ER100 gene therapy enters first human trial targeting aging reversal
Signals InboxJuly 12, 2026Gene Therapy
Life Biosciences has dosed the first participant with ER-100, making it the first partial epigenetic reprogramming therapy tested in humans. The real tension is not whether it can make people younger. It is whether three genes can safely restore function in damaged human nerve cells without pushing them too far backward.
ER100 is a new drug and potential gene therapy currently in its first clinical trial with 12 participants. The mechanism is not symptom management and not disease treatment. It targets the biological switch at the cellular level, instructing cells to revert to a different… pic.twitter.com/22Q41XeTtj
— Dr. Gabrielle Lyon (@drgabriellelyon) July 12, 2026
Q1What actually happened?
Life Biosciences announced that the first participant received ER-100 in June 2026. It is the first therapy based on partial epigenetic reprogramming to enter human testing. One correction to the viral post: the official trial plans to enroll up to 18 people, including 12 with glaucoma and six with NAION.
Q2Is this really an anti-aging drug?
Not in the drink-this-and-live-forever sense. ER-100 is being tested as a treatment for damaged optic nerves. Its bigger idea is that aging cells may lose useful instructions without permanently losing the ability to function. The therapy tries to restore part of those instructions and make the cells act younger.
Q3How does ER-100 work?
It uses a viral vector to deliver three genes called OCT4, SOX2, and KLF4 into retinal ganglion cells. These are three of the four famous Yamanaka factors used to reset cell identity. Life Biosciences leaves out MYC, the fourth factor, and controls gene activity with doxycycline because uncontrolled reprogramming could create serious safety problems.
Q4Why start with the eye?
The eye gives researchers a contained place to test the idea. Doctors can inject one eye, examine it directly, track vision, and compare changes over time without exposing the whole body. Glaucoma and NAION also destroy retinal nerve cells that current treatments generally cannot rebuild once they are lost.
Q5What evidence got it this far?
Life Biosciences previously tested the approach in monkeys with an optic-nerve injury similar to NAION. The company reported better visual function, improved axon measurements, and controlled expression of the three genes. Those results helped secure FDA authorization, but much of the detailed primate evidence has not yet gone through a full peer-reviewed publication.
Q6How big is this compared with other longevity projects?
It is small in patient count but far ahead in clinical timing. NewLimit recently raised $435 million and is preparing its own cellular-reprogramming trials, while Altos Labs launched with billions in funding. ER-100 got to humans first. That gives Life Biosciences an early lead, but an 18-person safety study is nowhere near proof that cellular aging can broadly be reversed.
Q7What should we watch next?
First, basic safety: inflammation, abnormal cell behavior, vision loss, or uncontrolled gene activity. Then comes the harder question: can treated patients regain measurable vision rather than simply decline more slowly? Positive data would not prove that human aging itself is reversible, but it could turn cellular rejuvenation from a wealthy founder obsession into a real drug platform.